The pericarditis drugs market is expected to grow substantially in the coming years. Increased prevalence of cardiovascular diseases, rising adoption of dual therapy for pericarditis treatment, and growing product approvals are some of the major factors driving the market.
Get a Sample Copy of Research Report (Use Corporate Mail Id for Quick Response) –
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=68099
Market Driver:
Rising cases of pericarditis globally is a key driver boosting demand for pericarditis drugs. According to statistics, the incidence of acute pericarditis ranges from 0.1% to 0.2% of hospitalized patients. Cardiovascular diseases also account for over 17 million deaths each year worldwide. Growing disease burden is prompting increased medication usage.
Market Trend:
Adoption of dual therapy combining aspirin and colchicine for idiopathic pericarditis treatment is a major trend in the market. Clinical trials have shown dual therapy to be more effective than aspirin monotherapy in reducing recurrence rates. This is expected to increase preference for combination drug regimens.
Market Challenge:
Side effects of anti-inflammatory drugs used to treat pericarditis pose a challenge for market players. Drugs like aspirin and colchicine can cause gastrointestinal issues, bleeding, and other complications. Managing drug safety remains a key concern.
Opportunity:
Asia Pacific presents lucrative growth opportunities for market participants. Rising healthcare spending, growing patient pool, and increasing focus on cardiovascular healthcare infrastructure are factors that will drive the APAC market.